Evaluating the safety and efficacy of combination immune checkpoint inhibitors and chemotherapy treatment in extensive-stage small cell lung cancer
The combination of ICIs and chemotherapy can afford better survival outcomes for ES-SCLC patients, especially in individuals suffering from brain metastases, and they should thus be considered as promising first-line treatment options. However, careful management of immune-related adverse events is crucial.
Authors
- Ning Su (ORCID: https://orcid.org/0000-0001-8738-514X)
- Lei An (ORCID: https://orcid.org/0000-0002-9778-2787)
- Yanyang Li (ORCID: https://orcid.org/0000-0003-4725-8570)
- Wenchang Cen (ORCID: https://orcid.org/0000-0001-7505-5522)
- Weifeng Zou (ORCID: https://orcid.org/0000-0002-6514-0704)
- Jizhen Liang
- Xiang Li (ORCID: https://orcid.org/0000-0002-0016-6233)
- Lei Li (ORCID: https://orcid.org/0000-0001-9910-5600)
- Yalin Xie
- Yun Jin (ORCID: https://orcid.org/0000-0002-3055-6734)
- Hongxu Lu
Institutions
- Jinan University (CN)
- Qujiang People's Hospital (CN)
- State Key Laboratory of Respiratory Disease (CN)
- Guangzhou Chest Hospital (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-05-05
- DOI
- https://doi.org/10.1007/s12672-025-02440-3
- Citations
- 1
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.05